Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal health in children with cystic fibrosis
Improvements in tummy and bowel symptoms after short and longer term Elexacaftor / Tezacaftor / Ivacaftor therapy (ETI)
Diabetes is associated with an increased burden of tummy and bowel symptoms in adults with cystic fibrosis
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging
